Pasithea Therapeutics Corp. (KTTA)
KTTA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.4238
-5.30% on the day
Market cap
$14.2M
Nano cap
Revenue
No annual revenue filed since the period ending 2022-12-31
Net income
No annual revenue filed since the period ending 2022-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | KTTA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001841330 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
No annual revenue filed since the period ending 2022-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 | POS AM | 2026-01-26 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-30 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-09-16 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-08-07 |
Source: SEC EDGAR submissions feed, 343 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RKTO | Rocket One Inc. | $0.5708 | -4.85% | $14.2M |
| TVRD | Tvardi Therapeutics Inc. | $1.04 | -1.89% | $13.9M |
| ALLR | Allarity Therapeutics Inc. | $0.8699 | +1.14% | $13.8M |
| HIND | Vyome Holdings Inc. | $1.97 | -1.99% | $13.8M |
| PTN | Palatin Technologies Inc. | $8.19 | -4.21% | $14.6M |
| DARE | Dare Bioscience Inc. | $0.7477 | -0.32% | $14.7M |
| GTBP | GT Biopharma Inc. | $6.50 | -4.41% | $13.4M |
| LPCN | Lipocine Inc. | $1.62 | -2.41% | $13.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier